ClinicalTrials.gg

Program

zigakibart

Also written as “BION-1301”, “BION-1301 Single Dose” and “BION-1301 Multiple Doses”.

In Novartis's pipeline, Anti-APRIL. Its studies are mostly in Glomerulonephritis, IGA · Multiple Myeloma, led by Novartis.

Furthest: phase 3, since May 2, 20236 company-led studies, 3 open or runningNext primary completion: Aug 10, 2027 (phase 3)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Novartis63 open or runningphase 3since May 2, 2023Nov 3, 2017Aug 10, 2027phase 3 · NCT05852938
  • Named in Novartis’s own pipeline as FUB523 (zigakibart), phase 3, as of Nov 16, 2026 (source).

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Nov 3, 2017First study: phase 2 study in Multiple MyelomaFirst studyNCT03340883 · 21 enrolled · United States
  2. Apr 21, 2019Phase 2 study in Glomerulonephritis, IGANCT03945318 · 103 enrolled · United States, South Korea, United Kingdom
  3. Aug 17, 2022Phase 1 study in Healthy VolunteerNCT05508204 · 36 enrolled · United States
  4. May 2, 2023Phase 3 study in Glomerulonephritis, IGANCT05852938 · 383 enrolled · United States, Argentina, Australia and more
  5. Feb 21, 2025Phase 3 study in Kidney DiseasesNCT06858319 · 220 planned · United States, Argentina, Australia and more
  6. Aug 21, 2025Phase 2 study in Glomerulonephritis, IGANCT07146906 · 32 planned · United States, Brazil, China and more

Ahead

  1. Aug 10, 2027Primary completion: phase 3 study in Glomerulonephritis, IGANCT05852938
  2. Jul 12, 2030Primary completion: phase 2 study in Glomerulonephritis, IGANCT07146906
  3. Jun 25, 2031Primary completion: phase 3 study in Kidney DiseasesNCT06858319

TargetBeta

“Anti-APRIL”the company's pipeline, read by Claude · source
“A humanized monoclonal antibody targeting a proliferation-inducing ligand (APRIL; tumor necrosis factor ligand superfamily member 13; TNFSF13), ”NCIt, by rule

Other programs on TNFSF13

ProgramCompanyFurthest phaseStudies
sibeprenlimabruleOtsukaphase 38

Studies

All 6 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT07146906Glomerulonephritis, IGA · United States, Brazil, China and more2RecruitingJul 12, 203032
NCT06858319Kidney Diseases · United States, Argentina, Australia and more3RecruitingJun 25, 2031220
NCT05852938Glomerulonephritis, IGA · United States, Argentina, Australia and more3Active, not recruitingAug 10, 2027383
NCT05508204Healthy Volunteer · United States1CompletedDec 16, 202236
NCT03945318Glomerulonephritis, IGA · United States, South Korea, United Kingdom2CompletedJun 10, 2026103
NCT03340883Multiple Myeloma · United States2TerminatedJun 13, 201921

How it is read

Names in the registry

  • “BION-1301”, 3 entries
  • “zigakibart”, 2 entries
  • “BION-1301 Single Dose”, 2 entries
  • “BION-1301 Multiple Doses”, 1 entry

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.